Free Trial

Pharming Group (PHAR) Competitors

$8.83
+0.30 (+3.52%)
(As of 07/17/2024 ET)

PHAR vs. DCPH, AMRX, JANX, PTGX, EWTX, VERA, GMTX, HRMY, GPCR, and MRVI

Should you be buying Pharming Group stock or one of its competitors? The main competitors of Pharming Group include Deciphera Pharmaceuticals (DCPH), Amneal Pharmaceuticals (AMRX), Janux Therapeutics (JANX), Protagonist Therapeutics (PTGX), Edgewise Therapeutics (EWTX), Vera Therapeutics (VERA), Gemini Therapeutics (GMTX), Harmony Biosciences (HRMY), Structure Therapeutics (GPCR), and Maravai LifeSciences (MRVI). These companies are all part of the "pharmaceutical preparations" industry.

Pharming Group vs.

Pharming Group (NASDAQ:PHAR) and Deciphera Pharmaceuticals (NASDAQ:DCPH) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, profitability, analyst recommendations, institutional ownership, earnings, valuation, risk, media sentiment and community ranking.

Pharming Group currently has a consensus target price of $37.00, suggesting a potential upside of 318.08%. Deciphera Pharmaceuticals has a consensus target price of $24.17, suggesting a potential downside of 5.54%. Given Pharming Group's stronger consensus rating and higher possible upside, research analysts plainly believe Pharming Group is more favorable than Deciphera Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Pharming Group
0 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
3.00
Deciphera Pharmaceuticals
0 Sell rating(s)
7 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.30

Pharming Group has a beta of 0.15, meaning that its stock price is 85% less volatile than the S&P 500. Comparatively, Deciphera Pharmaceuticals has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500.

In the previous week, Pharming Group had 4 more articles in the media than Deciphera Pharmaceuticals. MarketBeat recorded 5 mentions for Pharming Group and 1 mentions for Deciphera Pharmaceuticals. Pharming Group's average media sentiment score of 1.37 beat Deciphera Pharmaceuticals' score of 0.00 indicating that Pharming Group is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Pharming Group
3 Very Positive mention(s)
0 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Deciphera Pharmaceuticals
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Pharming Group has higher revenue and earnings than Deciphera Pharmaceuticals. Pharming Group is trading at a lower price-to-earnings ratio than Deciphera Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pharming Group$245.32M2.42-$10.55M-$0.16-55.19
Deciphera Pharmaceuticals$174.91M12.65-$194.94M-$2.21-11.58

0.0% of Pharming Group shares are held by institutional investors. Comparatively, 71.0% of Deciphera Pharmaceuticals shares are held by institutional investors. 2.1% of Pharming Group shares are held by company insiders. Comparatively, 4.7% of Deciphera Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Pharming Group has a net margin of -4.01% compared to Deciphera Pharmaceuticals' net margin of -108.86%. Pharming Group's return on equity of -4.61% beat Deciphera Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Pharming Group-4.01% -4.61% -2.18%
Deciphera Pharmaceuticals -108.86%-52.42%-40.05%

Deciphera Pharmaceuticals received 308 more outperform votes than Pharming Group when rated by MarketBeat users. Likewise, 64.91% of users gave Deciphera Pharmaceuticals an outperform vote while only 52.17% of users gave Pharming Group an outperform vote.

CompanyUnderperformOutperform
Pharming GroupOutperform Votes
12
52.17%
Underperform Votes
11
47.83%
Deciphera PharmaceuticalsOutperform Votes
320
64.91%
Underperform Votes
173
35.09%

Summary

Pharming Group beats Deciphera Pharmaceuticals on 10 of the 18 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PHAR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

PHAR vs. The Competition

MetricPharming GroupPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$594.61M$7.16B$5.28B$8.51B
Dividend YieldN/A2.75%2.75%4.02%
P/E Ratio-55.3113.85128.4016.95
Price / Sales2.42483.252,284.06104.97
Price / Cash89.3633.3235.1433.66
Price / Book2.715.934.974.55
Net Income-$10.55M$146.62M$110.24M$215.97M
7 Day Performance3.76%6.33%5.41%5.85%
1 Month Performance7.03%8.28%8.16%7.22%
1 Year Performance-27.15%-1.25%7.04%3.86%

Pharming Group Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DCPH
Deciphera Pharmaceuticals
0.6493 of 5 stars
0.65 / 5 stars
$25.59
flat
$24.17
-5.5%
+82.7%$2.21B$174.91M-11.58355News Coverage
AMRX
Amneal Pharmaceuticals
1.2414 of 5 stars
1.24 / 5 stars
$7.10
+4.3%
$8.25
+16.2%
+150.8%$2.19B$2.39B-12.687,700Short Interest ↑
News Coverage
JANX
Janux Therapeutics
2.1515 of 5 stars
2.15 / 5 stars
$41.55
-0.3%
$66.29
+59.5%
+272.2%$2.15B$8.08M-34.0668Short Interest ↑
Gap Down
PTGX
Protagonist Therapeutics
2.043 of 5 stars
2.04 / 5 stars
$34.78
+0.8%
$38.00
+9.3%
+78.0%$2.04B$60M14.25112Positive News
EWTX
Edgewise Therapeutics
1.389 of 5 stars
1.39 / 5 stars
$21.52
-5.8%
$33.20
+54.3%
+207.5%$2.01BN/A-13.8892
VERA
Vera Therapeutics
1.2017 of 5 stars
1.20 / 5 stars
$36.54
+4.2%
$42.86
+17.3%
+119.8%$2.00BN/A-17.8251News Coverage
Positive News
GMTX
Gemini Therapeutics
0 of 5 stars
0.00 / 5 stars
$45.80
-2.5%
N/A+6.6%$1.98BN/A-45.8031Gap Up
HRMY
Harmony Biosciences
4.0898 of 5 stars
4.09 / 5 stars
$33.52
-3.0%
$41.67
+24.3%
-1.8%$1.96B$617.51M14.51246Positive News
GPCR
Structure Therapeutics
1.4869 of 5 stars
1.49 / 5 stars
$41.83
+6.1%
$85.25
+103.8%
+32.5%$1.95BN/A-54.3293Gap Down
MRVI
Maravai LifeSciences
3.1723 of 5 stars
3.17 / 5 stars
$7.72
+2.0%
$11.44
+48.2%
-28.0%$1.94B$288.95M-7.80650

Related Companies and Tools

This page (NASDAQ:PHAR) was last updated on 7/17/2024 by MarketBeat.com Staff

From Our Partners